SpringerProtocols: Abstract: Application of Recombinant Antibodies in Cancer Patients

Application of Recombinant Antibodies in Cancer Patients

By: Jürgen Krauss³, Michaela Arndt³, Michael Pfreundschuh⁴

Abstract

Full Text

Download PDF (176K)

As a consequence of the invention of the hybridoma technology by Köhler and Milstein (1), many monoclonal antibodies (MAbs) have been evaluated in clinical trials since the early 1980s. Clinical outcomes were generally poor (2–5), with the notable exception of marked tumor responses, including long-term remissions of patients with malignant B-cell lymphoma who were treated with patient-specific antiidiotypic antibodies (6–8). The main factors responsible for these initial shortcomings were related to the immunogenicity of the murine protein, to modulation of targeted antigens, and to the poor ability of these antibodies to sufficiently mediate antibody-dependent effector functions in humans.

Affiliation(s): (3) National Cancer Institute at Frederick, Frederick, MD
(4) Universitätskliniken des Saarlandes, Innere Medizin I, Homburg, Germany

Book Title: Recombinant Antibodies for Cancer Therapy: Methods and Protocols

Series: Methods in Molecular Biology | Volume: 207 | Pub. Date: Sep-16-2002 | Page Range: 27-53 | DOI: 10.1385/1-59259-334-8:27

Subject: Cancer Research

References

Download References

1.	Köhler G. and Milstein C. (1975). Continuous culture of fused cells secreting antibody of predefined specifity. Nature 256, 495–497.

2.	Ritz J., Pesando J. M., Sallan S. E., Clavell L. A., Notis-McConarty J., Rosenthal P., and Schlossman S. F. (1981). Serotherapy of acute lymphoblastic leukemia with monoclonal antibody. Blood 58, 141–152.

3.	Miller R. A., Oseroff A. R., Stratte P. T., and Levy R. (1983). Monoclonal antibody therapeutic trials in seven patients with T-cell lymphoma. Blood 62, 988–995.

4.	Dillman R. O., Shawler D. L., Dillman J. B., and Royston I. (1984). Therapy of chronic lymphocytic leukemia and cutaneous T-cell lymphoma with T101 monoclonal antibody. J. Clin. Oncol. 2, 881–891.

5.	Foon K. A., Schroff R. W., Bunn P. A., Mayer D., Abrams P. G., Fer M., et al. (1984). Effects of monoclonal antibody therapy in patients with chronic lymphocytic leukemia. Blood 64, 1085–1093.

6.	Meeker T. C., Lowder J., Maloney D. G., Miller R. A., Thielemans K., Warnke R., and Levy R. (1985). A clinical trial of anti-idiotype therapy for B cell malignancy. Blood 65, 1349–1363.

7.	Brown S. L., Miller R. A., Horning S. J., Czerwinski D., Hart S. M., McElderry R., et al. (1989). Treatment of B-cell lymphomas with anti-idiotype antibodies alone and in combination with alpha interferon. Blood 73, 651–661.

8.	Davis T. A., Maloney D. G., Czerwinski D. K., Liles T. M., and Levy R. (1998). Antiidiotype antibodies can induce long-term complete remissions in non-Hodgkin’s lymphoma without eradicating the malignant clone. Blood 92, 1184–1190.

9.	Brack C. and Tonegawa S. (1977). Variable and constant parts of the immunoglobulin light chain gene of a mouse myeloma cell are 1250 nontranslated bases apart. Proc. Natl. Acad. Sci. USA 74, 5652–5656.

10.	Tonegawa S., Brack C., Hozumi N., and Schuller R. (1977). Cloning of an immunoglobulin variable region gene from mouse embryo. Proc. Natl. Acad. Sci. USA 74, 3518–3522.

11.	Meselson M. and Yuan R. (1968). DNA restriction enzyme from E. coli. Nature 217, 1110–1114.

12.	Boulianne G. L., Hozumi N., and Shulman M. J. (1984). Production of functional chimaeric mouse/human antibody. Nature 312, 643–646.

13.	Morrison S. L., Johnson M. J., Herzenberg L. A., and Oi V. T. (1984). Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains. Proc. Natl. Acad. Sci. USA 81, 6851–6855.

14.	Neuberger M. S., Williams G. T., and Fox R. O. (1984). Recombinant antibodies possessing novel effector functions. Nature 312, 604–608.

15.	LoBuglio A. F., Wheeler R. H., Trang J., Haynes A., Rogers K., Harvey E. B., et al. (1989). Mouse/human chimeric antibody in man: kinetics and immune response. Proc. Natl. Acad. Sci. USA 86, 4220–4224.

16.	Khazaeli M. B., Saleh M. N., Liu T. P., Meredith R. F., Wheeler R. H., Baker T. S., et al. (1991). Pharmacokinetics and immune response of 131I-chimeric mouse/human B72.3 (human gamma 4) monoclonal antibody in humans. Cancer Res. 51, 5461–5466.

17.	Maloney D. G., Liles T. M., Czerwinski D. K., Waldichuk C., Rosenberg J., Grillo-Lopez A., and Levy R. (1994). Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood 84, 2457–2466.

18.	Maloney D. G., Grillo-Lopez A. J., White C. A., Bodkin D., Schilder R. J., Neidhart J. A., et al. (1997). IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin’s lymphoma. Blood 90, 2188–2195.

19.	Davis T. A., White C. A., Grillo-Lopez A. J., Velasquez W. S., Link B., Maloney D. G., et al. (1999). Single-agent monoclonal antibody efficacy in bulky non-Hodgkin’s lymphoma: results of a phase II trial of rituximab. J. Clin. Oncol. 17, 1851–1857.

20.	Maloney D. G., Grillo-Lopez A. J., Bodkin D. J., White C. A., Liles T. M., Royston I., et al. (1997). IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin’s lymphoma. J. Clin. Oncol. 15, 3266–3274.

21.	Berinstein N. L., Grillo-Lopez A. J., White C. A., Bence-Bruckler I., Maloney D., et al. (1998). Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin’s lymphoma. Ann. Oncol. 9, 995–1001.

22.	Bruggemann M., Williams G. T., Bindon C. I., Clark M. R., Walker M. R., Jefferis R., et al. (1987). Comparison of the effector functions of human immunoglobulins using a matched set of chimeric antibodies. J. Exp. Med. 166, 1351–1361.

23.	Shaw D. R., Khazaeli M. B., and LoBuglio A. F. (1988). Mouse/human chimeric antibodies to a tumor-associated antigen: biologic activity of the four human IgG subclasses. J. Natl. Cancer Inst. 80, 1553–1559.

24.	Abdullah N., Greenman J., Pimenidou A., Topping K. P., and Monson J. R. (1999). The role of monocytes and natural killer cells in mediating antibody-dependent lysis of colorectal tumour cells. Cancer Immunol. Immunother. 48, 517–524.

25.	Golay J., Zaffaroni L., Vaccari T., Lazzari M., Borleri G. M., Bernasconi S., et al. (2000). Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood 95, 3900–3908.

26.	Steplewski Z., Sun L. K., Shearman C. W., Ghrayeb J., Daddona P., and Koprowski H. (1988). Biological activity of human-mouse IgG1, IgG2, IgG3, and IgG4 chimeric monoclonal antibodies with antitumor specificity. Proc. Natl. Acad. Sci. USA 85, 4852–4856.

27.	Clynes R. A., Towers T. L., Presta L. G., and Ravetch J. V. (2000). Inhibitory Fcreceptors modulate in vivo cytoxicity against tumor targets. Nat. Med. 6, 443–446.

28.	Jones P. T., Dear P. H., Foote J., Neuberger M. S., and Winter G. (1986). Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature 321, 522–525.

29.	Chothia C. and Lesk A. M. (1987). Canonical structures for the hypervariable regions of immunoglobulins. J. Mol. Biol. 196, 901–917. <Occurrence Type="DOI"><Handle>10.1016/0022-2836(87)90412-8</Handle></Occurrence>

30.	Chothia C., Lesk A. M., Tramontano A., Levitt M., Smith-Gill S. J., Air G., et al. (1989). Conformations of immunoglobulin hypervariable regions. Nature 342, 877–883.

31.	Queen C., Schneider W. P., Selick H. E., Payne P. W., Landolfi N. F., Duncan J. F., et al. (1989). A humanized antibody that binds to the interleukin 2 receptor. Proc. Natl. Acad. Sci. USA 86, 10,029–10,033.

32.	Kettleborough C. A., Saldanha J., Heath V. J., Morrison C. J., and Bendig M. M. (1991). Humanization of a mouse monoclonal antibody by CDR-grafting: the importance of framework residues on loop conformation. Protein Eng. 4, 773–783.

33.	Co M. S., Avdalovic N. M., Caron P. C., Avdalovic M. V., Scheinberg D. A., and Queen, C. (1992). Chimeric and humanized antibodies with specificity for the CD33 antigen. J. Immunol. 148, 1149–1154.

34.	Roberts S., Cheetham J. C., and Rees A. R. (1987). Generation of an antibody with enhanced affinity and specificity for its antigen by protein engineering. Nature 328, 731–734.

35.	Riechmann L., Clark M., Waldmann H., and Winter G. (1988). Reshaping human antibodies for therapy. Nature 332, 323–327.

36.	Roguska M. A., Pedersen J. T., Keddy C. A., Henry A. H., Searle S. J., Lambert J. M., et al. (1994). Humanization of murine monoclonal antibodies through variable domain resurfacing. Proc. Natl. Acad. Sci. USA 91, 969–973.

37.	Glennie M. J. and Johnson P. W. (2000). Clinical trials of antibody therapy. Immunol. Today 21, 403–410. <Occurrence Type="DOI"><Handle>10.1016/S0167-5699(00)01669-8</Handle></Occurrence>

38.	Behr T. M., Wormann B., Gramatzki M., Riggert J., Gratz S., Behe M., et al. (1999). Low-versus high-dose radioimmunotherapy with humanized anti-CD22 or chimeric anti-CD20 antibodies in a broad spectrum of B cell-associated malignancies. Clin. Cancer Res. 5, 3304s–3314s.

39.	Juweid M. E., Stadtmauer E., Hajjar G., Sharkey R. M., Suleiman S., Luger S., et al. (1999). Pharmacokinetics, dosimetry, and initial therapeutic results with 131I-and (111)In-/90Y-labeled humanized LL2 anti-CD22 monoclonal antibody in patients with relapsed, refractory non-Hodgkin’s lymphoma. Clin. Cancer Res. 5, 3292s–3303s.

40.	Sievers E. L., Appelbaum F. R., Spielberger R. T., Forman S. J., Flowers D., Smith F. O., et al. (1999). Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a phase I study of an anti-CD33 calicheamicin immunoconjugate. Blood 93, 3678–3684.

41.	Steffens M. G., Boerman O. C., de Mulder P. H., Oyen W. J., Buijs W. C., Witjes J. A., et al. (1999). Phase I radioimmunotherapy of metastatic renal cell carcinoma with 131I-labeled chimeric monoclonal antibody G250. Clin. Cancer Res. 5, 3268s–3274s.

42.	Tolcher A. W., Sugarman S., Gelmon K. A., Cohen R., Saleh M., Isaacs C., et al. (1999). Randomized phase II study of BR96-doxorubicin conjugate in patients with metastatic breast cancer. J. Clin. Oncol. 17, 478–484.

43.	Saleh M. N., Sugarman S., Murray J., Ostroff J. B., Healey D., Jones D., et al. (2000). Phase I trial of the anti-Lewis Y drug immunoconjugate BR96-doxorubicin in patients with lewis Y-expressing epithelial tumors. J. Clin. Oncol. 18, 2282–2292.

44.	Miller J. L. (2000). FDA approves antibody-directed cytotoxic agent for acute myeloid leukemia. Am. J. Health Syst. Pharm. 57, 1202, 1204.

45.	Shalaby M. R., Shepard H. M., Presta L., Rodrigues M. L., Beverley P. C., Feldmann M., and Carter P. (1992). Development of humanized bispecific antibodies reactive with cytotoxic lymphocytes and tumor cells overexpressing the HER2 protooncogene. J. Exp. Med. 175, 217–225.

46.	Zhu Z., Lewis G. D., and Carter P. (1995). Engineering high affinity humanized antip185HER2/anti-CD3 bispecific F(ab′)2 for efficient lysis of p185HER2 overexpressing tumor cells. Int. J. Cancer 62, 319–324.

47.	Luiten R. M., Coney L. R., Fleuren G. J., Warnaar S. O., and Litvinov S. V. (1996). Generation of chimeric bispecific G250/anti-CD3 monoclonal antibody, a tool to combat renal cell carcinoma. Br. J. Cancer 74, 735–744.

48.	Ridgway J. B., Presta L. G., and Carter P. (1996). ‘Knobs-into-holes’ engineering of antibody CH3 domains for heavy chain heterodimerization. Protein Eng. 9, 617–621.

49.	Keler T., Graziano R. F., Mandal A., Wallace P. K., Fisher J., Guyre P. M., et al. (1997). Bispecific antibody-dependent cellular cytotoxicity of HER2/neu-overexpressing tumor cells by Fc gamma receptor type I-expressing effector cells. Cancer Res. 57, 4008–4014.

50.	van Ojik H. H., Repp R., Groenewegen G., Valerius T., and van de Winkel J. G. (1997). Clinical evaluation of the bispecific antibody MDX-H210 (anti-Fc gamma RI · anti-HER-2/neu) in combination with granulocyte-colony-stimulating factor (filgrastim) for treatment of advanced breast cancer. Cancer Immunol. Immunother. 45, 207–209.

51.	Posey J. A., Raspet R., Verma U., Deo Y. M., Keller T., Marshall J. L., et al. (1999). A pilot trial of GM-CSF and MDX-H210 in patients with erbB-2-positive advanced malignancies. J. Immunother. 22, 371–379.

52.	Lewis L. D., Cole B. F., Wallace P. K., Fisher J. L., Waugh M., Guyre P. M., et al. (2001). Pharmacokinetic-pharmacodynamic relationships of the bispecific antibody MDX-H210 when administered in combination with interferon gamma: a multiple-dose phase-I study in patients with advanced cancer which overexpresses HER-2/neu. J. Immunol. Methods 248, 149–165. <Occurrence Type="DOI"><Handle>10.1016/S0022-1759(00)00355-0</Handle></Occurrence>

53.	Skerra A. and Pluckthun A. (1988). Assembly of a functional immunoglobulin Fv fragment in Escherichia coli. Science 240, 1038–1041.

54.	Better M., Chang C. P., Robinson R. R., and Horwitz A. H. (1988). Escherichia coli secretion of an active chimeric antibody fragment. Science 240, 1041–1043.

55.	Glockshuber R., Malia M., Pfitzinger I., and Plückthun A. (1990). A comparison of strategies to stabilize immunoglobulin Fv fragments. Biochemistry 29, 1362–1367.

56.	Huston J. S., Levinson D., Mudgett-Hunter M., Tai M. S., Novotny J., Margolies M. N., et al. (1988). Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli. Proc. Natl. Acad. Sci. USA 85, 5879–5883.

57.	Bird R. E., Hardman K. D., Jacobson J. W., Johnson S., Kaufman B. M., Lee S. M., et al. (1988). Single-chain antigen-binding proteins [published erratum appears in Science 1989 Apr 28;244(4903):409]. Science 242, 423–426.

58.	Brinkmann U., Reiter Y., Jung S. H., Lee B., and Pastan I. (1993). A recombinant immunotoxin containing a disulfide-stabilized Fv fragment. Proc. Natl. Acad. Sci. USA 90, 7538–7542.

59.	Reiter Y., Brinkmann U., Jung S. H., Lee B., Kasprzyk P. G., King C. R., and Pastan I. (1994). Improved binding and antitumor activity of a recombinant anti-erbB2 immunotoxin by disulfide stabilization of the Fv fragment. J. Biol. Chem. 269, 18,327–18,331.

60.	Chaudhary V. K., FitzGerald D. J., Adhya S., and Pastan I. (1987). Activity of a recombinant fusion protein between transforming growth factor type alpha and Pseudomonas toxin. Proc. Natl. Acad. Sci. USA 84, 4538–4542.

61.	Chaudhary V. K., Queen C., Junghans R. P., Waldmann T. A., FitzGerald D. J., and Pastan I. (1989). A recombinant immunotoxin consisting of two antibody variable domains fused to Pseudomonas exotoxin. Nature 339, 394–397.

62.	Batra J. K., Fitzgerald D. J., Chaudhary V. K., and Pastan I. (1991). Single-chain immunotoxins directed at the human transferrin receptor containing Pseudomonas exotoxin A or diphtheria toxin: anti-TFR(Fv)-PE40 and DT388-anti-TFR(Fv). Mol. Cell. Biol. 11, 2200–2205.

63.	Brinkmann U., Pai L. H., FitzGerald D. J., Willingham M., and Pastan I. (1991). B3(Fv)-PE38KDEL, a single-chain immunotoxin that causes complete regression of a human carcinoma in mice. Proc. Natl. Acad. Sci. USA 88, 8616–8620.

64.	Siegall C. B. (1995). Targeted therapy of carcinomas using BR96 sFv-PE40, a singlechain immunotoxin that binds to the Le(y) antigen. Semin. Cancer Biol. 6, 289–295.

65.	Newton D. L., Nicholls P. J., Rybak S. M., and Youle R. J. (1994). Expression and characterization of recombinant human eosinophil-derived neurotoxin and eosinophilderived neurotoxin-anti-transferrin receptor sFv. J. Biol. Chem. 269, 26,739–26,745.

66.	Newton D. L., Xue Y., Olson K. A., Fett J. W., and Rybak S. M. (1996). Angiogenin single-chain immunofusions: influence of peptide linkers and spacers between fusion protein domains. Biochemistry 35, 545–553.

67.	Zewe M., Rybak S. M., Dubel S., Coy J. F., Welschof M., Newton D. L., and Little M. (1997). Cloning and cytotoxicity of a human pancreatic RNase immunofusion. Immunotechnology 3, 127–136. <Occurrence Type="DOI"><Handle>10.1016/S1380-2933(97)00070-5</Handle></Occurrence>

68.	Bosslet K., Czech J., Lorenz P., Sedlacek H. H., Schuermann M., and Seemann G. (1992). Molecular and functional characterisation of a fusion protein suited for tumour specific prodrug activation. Br. J. Cancer 65, 234–238.

69.	Goshorn S. C., Svensson H. P., Kerr D. E., Somerville J. E., Senter P. D., and Fell H. P. (1993). Genetic construction, expression, and characterization of a single chain anticarcinoma antibody fused to beta-lactamase. Cancer Res. 53, 2123–2127.

70.	Rodrigues M. L., Presta L. G., Kotts C. E., Wirth C., Mordenti J., Osaka G., et al. (1995). Development of a humanized disulfide-stabilized anti-p185HER2 Fv-betalactamase fusion protein for activation of a cephalosporin doxorubicin prodrug. Cancer Res. 55, 63–70.

71.	Michael N. P., Chester K. A., Melton R. G., Robson L., Nicholas W., Boden J. A., et. al. (1996). In vitro and in vivo characterisation of a recombinant carboxypeptidase G2:anti-CEA scFv fusion protein. Immunotechnology 2, 47–57. <Occurrence Type="DOI"><Handle>10.1016/1380-2933(96)00033-4</Handle></Occurrence>

72.	Haisma H. J., Sernee M. F., Hooijberg E., Brakenhoff R. H., vd Meulen-Muileman I. H., et al. (1998). Construction and characterization of a fusion protein of single-chain anti-CD20 antibody and human beta-glucuronidase for antibody-directed enzyme prodrug therapy. Blood 92, 184–190.

73.	Colcher D., Pavlinkova G., Beresford G., Booth B. J., and Batra S. K. (1999). Singlechain antibodies in pancreatic cancer. Ann. NY Acad. Sci. 880, 263–280.

74.	Rosenblum M. G., Horn S. A., and Cheung L. H. (2000). A novel recombinant fusion toxin targeting HER-2/NEU-over-expressing cells and containing human tumor necrosis factor. Int. J. Cancer 88, 267–273. <Occurrence Type="DOI"><Handle>10.1002/1097-0215(20001015)88:2<267::AID-IJC19>3.0.CO;2-G</Handle></Occurrence>

75.	Xu X., Clarke P., Szalai G., Shively J. E., Williams L. E., Shyr Y., Shi E., et al. (2000). Targeting and therapy of carcinoembryonic antigen-expressing tumors in transgenic mice with an antibody-interleukin 2 fusion protein. Cancer Res. 60, 4475–4484.

76.	Biragyn A., Tani K., Grimm M. C., Weeks S., and Kwak L. W. (1999). Genetic fusion of chemokines to a self tumor antigen induces protective, T-cell dependent antitumor immunity. Nature Biotechnol. 17, 253–258.

77.	Kostelny S. A., Cole M. S., and Tso J. Y. (1992). Formation of a bispecific antibody by the use of leucine zippers. J. Immunol. 148, 1547–1553.

78.	Pack P. and Pluckthun A. (1992). Miniantibodies: use of amphipathic helices to produce functional, flexibly linked dimeric FV fragments with high avidity in Escherichia coli. Biochemistry 31, 1579–1584.

79.	Holliger P., Prospero T., and Winter G. (1993). “Diabodies”: Small bivalent and bispecific antibody fragments. Proc. Natl. Acad. Sci. USA 90, 6444–6448.

80.	Gruber M., Schodin B. A., Wilson E. R., and Kranz D. M. (1994). Efficient tumor cell lysis mediated by a bispecific single chain antibody expressed in Escherichia coli. J. Immunol. 152, 5368–5374.

81.	Zhu Z., Presta L. G., Zapata G., and Carter P. (1997). Remodeling domain interfaces to enhance heterodimer formation. Protein Sci. 6, 781–788.

82.	Holliger P., Brissinck J., Williams R. L., Thielmans K., and Winter G. (1996). Specific killing of lymphoma cells by cytotoxic T-cells mediated by a bispecific diabody. Prot. Eng. 9, 299–305.

83.	Zhu Z., Zapata G., Shalaby R., Snedecor B., Chen H., and Carter P. (1996). High-Level secretion of a humanized bispecific diabody from Escherichia coli. Biotechnology 14, 192–196.

84.	Kipriyanov S. M., Moldenhauer G., Srauss G., and Little M. (1998). Bispecific CD3 · CD19 diabody for T cell-mediated lysis of malignant human B cells. Int. J. Cancer 77, 763–772. <Occurrence Type="DOI"><Handle>10.1002/(SICI)1097-0215(19980831)77:5<763::AID-IJC16>3.0.CO;2-2</Handle></Occurrence>

85.	Manzke O., Fitzgerald K. J., Holliger P., Klock J., Span M., Fleischmann B. H., et al. (1999). CD3X anti-nitrophenyl bispecific diabodies: universal Immunotherapeutic tools for retargeting T cells to tumors. Int. J. Cancer 82, 700–708. <Occurrence Type="DOI"><Handle>10.1002/(SICI)1097-0215(19990827)82:5<700::AID-IJC13>3.0.CO;2-2</Handle></Occurrence>

86.	Arndt M. A., Krauss J., Kipriyanov S. M., Pfreundschuh M., and Little M. (1999). A bispecific diabody that mediates natural killer cell cytotoxicity against xenotransplantated human Hodgkin’s tumors. Blood 94, 2562–2568.

87.	Coloma M. J. and Morrison S. L. (1997). Design and production of novel tetravalent bispecific antibodies. Nature Biotechnol. 15, 159–163.

88.	Alt M., Muller R., and Kontermann R. E. (1999). Novel tetravalent and bispecific IgGlike antibody molecules combining single-chain diabodies with the immunoglobulin gamma1 Fc or CH3 region. FEBS Lett. 454, 90–94. <Occurrence Type="DOI"><Handle>10.1016/S0014-5793(99)00782-6</Handle></Occurrence>

89.	Kipriyanov S. M., Moldenhauer G., Schuhmacher J., Cochlovius B., Von der Lieth C. W., Matys E. R., and Little M. (1999). Bispecific tandem diabody for tumor therapy with improved antigen binding and pharmacokinetics. J. Mol. Biol. 293, 41–56.

90.	Gross G. and Eshhar Z. (1992). Endowing T cells with antibody specificity using chimeric T cell receptors. FASEB J. 6, 3370–3378.

91.	Eshhar Z., Waks T., Gross G., and Schindler D. G. (1993). Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc. Natl. Acad. Sci. USA 90, 720–724.

92.	Hwu P., Shafer G. E., Treisman J., Schindler D. G., Gross G., Cowherd R., et al. (1993). Lysis of ovarian cancer cells by human lymphocytes redirected with a chimeric gene composed of an antibody variable region and the Fc receptor gamma chain. J. Exp. Med. 178, 361–366.

93.	Hombach A., Heuser C., Sircar R., Tillmann T., Diehl V., Kruis W., et al. (1997). T cell targeting of TAG72+ tumor cells by a chimeric receptor with antibody-like specificity for a carbohydrate epitope. Gastroenterology 113, 1163–1170.

94.	Hombach A., Schneider C., Sent D., Koch D., Willemsen R. A., Diehl V., et al. (2000). An entirely humanized CD3 zeta-chain signaling receptor that directs peripheral blood T cells to specific lysis of carcinoembryonic antigen-positive tumor cells. Int. J. Cancer 88, 115–120. <Occurrence Type="DOI"><Handle>10.1002/1097-0215(20001001)88:1<115::AID-IJC18>3.0.CO;2-E</Handle></Occurrence>

95.	Kreitman R. J., Wilson W. H., Bergeron K., Raggio M., Stetler-Stevenson M., FitzGerald D. J., and Pastan I. (2001). Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. N. Engl. J. Med. 26, 241–247.

96.	Kreitman R. J., Wilson W. H., White J. D., Stetler-Stevenson M., Jaffe E. S., Giardina S., et al. (2000). Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies. J. Clin. Oncol. 18, 1622–1636.

97.	Smith G. P. (1985). Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. Science 228, 1315–1317.

98.	McCafferty J., Griffiths A. D., Winter G., and Chiswell D. J. (1990). Phage antibodies: filamentous phage displaying antibody variable domains. Nature 348, 552–554.

99.	Saiki R. K., Scharf S., Faloona F., Mullis K. B., Horn G. T., Erlich H. A., and Arnheim N. (1985). Enzymatic amplification of beta-globin genomic sequences and restriction site analysis for diagnosis of sickle cell anemia. Science 230, 1350–1354.

100.	Orlandi R., Gussow D. H., Jones P. T., and Winter G. (1989). Cloning immunoglobulin variable domains for expression by the polymerase chain reaction. Proc. Natl. Acad. Sci. USA 86, 3833–3837.

101.	Sastry L., Alting-Mees M., Huse W. D., Short J. M., Sorge J. A., Hay B. N., et al. (1989). Cloning of the immunological repertoire in Escherichia coli for generation of monoclonal catalytic antibodies: construction of a heavy chain variable region-specific cDNA library. Proc. Natl. Acad. Sci. USA 86, 5728–5732.

102.	Marks J. D., Tristem M., Karpas A., and Winter G. (1991). Oligonucleotide primers for polymerase chain reaction amplification of human immunoglobulin variable genes and design of family-specific oligonucleotide probes. Eur. J. Immunol. 21, 985–991.

103.	Welschof M., Terness P., Kolbinger F., Zewe M., Dubel S., Dorsam H., et al. (1995). Amino acid sequence based PCR primers for amplification of rearranged human heavy and light chain immunoglobulin variable region genes. J. Immunol. Methods 179, 203–214. <Occurrence Type="DOI"><Handle>10.1016/0022-1759(94)00286-6</Handle></Occurrence>

104.	Barbas C. F., 3rd, Kang A. S., Lerner R. A., and Benkovic S. J. (1991). Assembly of combinatorial antibody libraries on phage surfaces: the gene III site. Proc. Natl. Acad. Sci. USA 88, 7978–7982.

105.	Breitling F., Dubel S., Seehaus T., Klewinghaus I., and Little M. (1991). A surface expression vector for antibody screening. Gene 104, 147–153. <Occurrence Type="DOI"><Handle>10.1016/0378-1119(91)90244-6</Handle></Occurrence>

106.	Hoogenboom H. R., Griffiths A. D., Johnson K. S., Chiswell D. J., Hudson P., and Winter G. (1991). Multi-subunit proteins on the surface of filamentous phage: methodologies for displaying antibody (Fab) heavy and light chains. Nucleic Acids Res. 19, 4133–4137.

107.	Cai X. and Garen A. (1995). Anti-melanoma antibodies from melanoma patients immunized with genetically modified autologous tumor cells: selection of specific antibodies from single-chain Fv fusion phage libraries. Proc. Natl. Acad. Sci. USA 92, 6537–6541.

108.	Pereira S., Van Belle P., Elder D., Maruyama H., Jacob L., Sivanandham M., et al. (1997). Combinatorial antibodies against human malignant melanoma. Hybridoma 16, 11–16.

109.	Welschof M., Terness P., Kipriyanov S. M., Stanescu D., Breitling F., Dorsam H., et al. (1997). The antigen-binding domain of a human IgG-anti-F(ab′)2 autoantibody. Proc. Natl. Acad. Sci. USA 94, 1902–1907.

110.	Clackson T., Hoogenboom H. R., Griffiths A. D., and Winter G. (1991). Making antibody fragments using phage display libraries. Nature 352, 624–628.

111.	Chester K. A., Begent R. H. J., Robson L., Keep P., Pedley R. B., Boden J. A., et al. (1994). Phage libraries for generation of clinically useful antibodies. Lancet 343, 455–456. <Occurrence Type="DOI"><Handle>10.1016/S0140-6736(94)92695-6</Handle></Occurrence>

112.	Kettleborough C. A., Ansell K. H., Allen R. W., Rosell-Vives E., Gussow D. H., and Bendig M. M. (1994). Isolation of tumor cell-specific single-chain Fv from immunized mice using phage-antibody libraries and the re-construction of whole antibodies from these antibody fragments. Eur. J. Immunol. 24, 952–958.

113.	Marks J. D., Hoogenboom H. R., Bonnert T. P., McCafferty J., Griffiths A. D., and Winter G. (1991). By-passing immunization. Human antibodies from V-gene libraries displayed on phage. J. Mol. Biol. 222, 581–597. <Occurrence Type="DOI"><Handle>10.1016/0022-2836(91)90498-U</Handle></Occurrence>

114.	Sheets M. D., Amersdorfer P., Finnern R., Sargent P., Lindquist E., Schier R., et al. (1998). Efficient construction of a large nonimmune phage antibody library: the production of high-affinity human single-chain antibodies to protein antigens. Proc. Natl. Acad. Sci. USA 95, 6157–6162.

115.	de Haard H. J., van Neer N., Reurs A., Hufton S. E., Roovers R. C., Henderikx P., et al. (1999). A large non-immunized human Fab fragment phage library that permits rapid isolation and kinetic analysis of high affinity antibodies. J. Biol. Chem. 274, 18,218–18,230.

116.	Little M., Welschof M., Braunagel M., Hermes I., Christ C., Keller A., et al. (1999). Generation of a large complex antibody library from multiple donors. J. Immunol. Methods 231, 3–9. <Occurrence Type="DOI"><Handle>10.1016/S0022-1759(99)00164-7</Handle></Occurrence>

117.	Barbas C. F., 3rd, Bain J. D., Hoekstra D. M., and Lerner R. A. (1992). Semisynthetic combinatorial antibody libraries: a chemical solution to the diversity problem. Proc. Natl. Acad. Sci. USA 89, 4457–4461.

118.	Hoogenboom H. R. and Winter G. (1992). By-passing immunisation. Human antibodies from synthetic repertoires of germline VH gene segments rearranged in vitro. J. Mol. Biol. 227, 381–388. <Occurrence Type="DOI"><Handle>10.1016/0022-2836(92)90894-P</Handle></Occurrence>

119.	Garrard L. J. and Henner D. J. (1993). Selection of an anti-IGF-1 Fab from a Fab phage library created by mutagenesis of multiple CDR loops. Gene 128, 103–109. <Occurrence Type="DOI"><Handle>10.1016/0378-1119(93)90160-5</Handle></Occurrence>

120.	Griffiths A. D., Williams S. C., Hartley O., Tomlinson I. M., Waterhouse P., Crosby W. L., et al. (1994). Isolation of high affinity human antibodies directly from large synthetic repertoires. EMBO J. 13, 3245–3260.

121.	Nissim A., Hoogenboom H. R., Tomlinson I. M., Flynn G., Midgley C., Lane D., and Winter G. (1994). Antibody fragments from a’ single pot’ phage display library as immunochemical reagents. EMBO J. 13, 692–698.

122.	Braunagel M. and Little M. (1997). Construction of a semisynthetic antibody library using trinucleotide oligos. Nucleic Acids Res. 25, 4690–4691.

123.	Knappik A., Ge L., Honegger A., Pack P., Fischer M., Wellnhofer G., et al. (2000). Fully synthetic human combinatorial antibody libraries (HuCAL) based on modular consensus frameworks and CDRs randomized with trinucl otides. J. Mol. Biol. 296, 57–86.

124.	Hanes J. and Pluckthun A. (1997). In vitro selection and evolution of functional proteins by using ribosome display. Proc. Natl. Acad. Sci. USA 94, 4937–4942.

125.	He M. and Taussig M. J. (1997). Antibody-ribosome-mRNA (ARM) complexes as efficient selection particles for in vitro display and evolution of antibody combining sites. Nucleic Acids Res. 25, 5132–5134.

126.	Hamers-Casterman C., Atarhouch T., Muyldermans S., Robinson G., Hamers C., Songa E. B., et al. (1993). Naturally occurring antibodies devoid of light chains. Nature 363, 446–448.

127.	Arbabi Ghahroudi M., Desmyter A., Wyns L., Hamers R., and Muyldermans S. (1997). Selection and identification of single domain antibody fragments from camel heavychain antibodies. FEBS Lett. 414, 521–526. <Occurrence Type="DOI"><Handle>10.1016/S0014-5793(97)01062-4</Handle></Occurrence>

128.	Muyldermans S. and Lauwereys M. (1999). Unique single-domain antigen binding fragments derived from naturally occurring camel heavy-chain antibodies. J. Mol. Recognit. 12, 131–140. <Occurrence Type="DOI"><Handle>10.1002/(SICI)1099-1352(199903/04)12:2<131::AID-JMR454>3.0.CO;2-M</Handle></Occurrence>

129.	Reiter Y., Schuck P., Boyd L. F., and Plaksin D. (1999). An antibody single-domain phage display library of a native heavy chain variable region: isolation of functional single-domain VH molecules with a unique interface. J. Mol. Biol. 290, 685–698.

130.	Begent R. H., Verhaar M. J., Chester K. A., Casey J. L., Green A. J., Napier M. P., (1996). Clinical evidence of efficient tumor targeting based on single-chain Fv antibody selected from a combinatorial library. Nat. Med. 2, 979–984.

131.	Mayer A., Chester K. A., Flynn A. A., and Begent R. H. (1999). Taking engineered anti-CEA antibodies to the clinic. J. Immunol. Methods 231, 261–273. <Occurrence Type="DOI"><Handle>10.1016/S0022-1759(99)00162-3</Handle></Occurrence>

132.	Carson D. A. and Freimark B. D. (1986). Human lymphocyte hybridomas and monoclonal antibodies. Adv. Immunol. 38, 275–311.

133.	Bruggemann M., Spicer C., Buluwela L., Rosewell I., Barton S., Surani M. A., and Rabbitts T. H. (1991). Human antibody production in transgenic mice: expression from 100 kb of the human IgH locus. Eur. J. Immunol. 21, 1323–1326.

134.	Taylor L. D., Carmack C. E., Schramm S. R., Mashayekh R., Higgins K. M., Kuo C. C., et al. (1992). A transgenic mouse that expresses a diversity of human sequence heavy and light chain immunoglobulins. Nucleic Acids Res. 20, 6287–6295.

135.	Lonberg N., Taylor L. D., Harding F. A., Trounstine M., Higgins K. M., Schramm S. R., et al. (1994). Antigen-specific human antibodies from mice comprising four distinct genetic modifications. Nature 368, 856–859.

136.	Nicholson I. C., Zou X., Popov A. V., Cook G. P., Corps E. M., Humphries S., et al. (1999). Antibody repertoires of four-and five-feature translocus mice carrying human immunoglobulin heavy chain and kappa and lambda light chain yeast artificial chromosomes. J. Immunol. 163, 6898–6906.

137.	Tomizuka K., Shinohara T., Yoshida H., Uejima H., Ohguma A., Tanaka S., et al. (2000). Double trans-chromosomic mice: maintenance of two individual human chromosome fragments containing Ig heavy and kappa loci and expression of fully human antibodies. Proc. Natl. Acad. Sci. USA 97, 722–727.

138.	Stashenko P., Nadler L. M., Hardy R., and Schlossman S. F. (1980). Characterization of a human B lymphocyte-specific antigen. J. Immunol. 125, 1678–1685.

139.	McLaughlin P., Grillo-Lopez A. J., Link B. K., Levy R., Czuczman M. S., Williams M. E., et al. (1998). Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J. Clin. Oncol. 16, 2825–2833.

140.	Coiffier B., Haioun C., Ketterer N., Engert A., Tilly H., Ma D., et al. (1998). Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood 92, 1927–1932.

141.	Coiffier B., Lepage E., Herbrecht R., Tilly H., Solal-Celigny P., Munck J. N., et al. (2000). Mabthera (Rituximab) plus CHOP is superior to CHOP alone in elderly patients with diffuse large B-cell lymphoma (DLCL): Interim results of a randomized GELA trial. Abstract #950 American Society of Hematology (ASH).

142.	Coiffier B., Lepage E., Gaulard P., Quesnel A., Bosly A., Christian B., et al. (2001). Prognostic factors affecting the efficacy of Rituximab plus CHOP (R-CHOP) therapy in elderly patients with diffuse large B-cell lymphoma (DLCL): results of a randomized GELA trial. Abstract #1131 Annual Meeting of American Society of Clinical Oncologists (ASCO).

143.	Vose J. M., Link B. K., Grossbard M. L., Czuczman M., Grillo-Lopez A., Gilman P., et al. (2001). Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin’s lymphoma. J. Clin. Oncol. 19, 389–397.

144.	Czuczman M. S., Grillo-Lopez A. J., White C. A., Saleh M., Gordon L., LoBuglio A. F., et al. (1999). Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J. Clin. Oncol. 17, 268–276.

145.	Colombat P., Salles G., Brousse N., Eftekhari P., Soubeyran P., Delwail V., et al. (2001). Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood 97, 101–106.

146.	Buckstein R., Imrie K., Spaner D., Potichnyj A., Robinson J. B., Nanji S., et al. (1999). Stem cell function and engraftment is not affected by “in vivo purging” with rituximab for autologous stem cell treatment for patients with low-grade non-Hodgkin’s lymphoma. Semin. Oncol. 26, 115–122.

147.	Coussens L., Yang-Feng T. L., Liao Y. C., Chen E., Gray A., McGrath J., et al. (1985). Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 230, 1132–1139.

148.	Slamon D. J., Clark G. M., Wong S. G., Levin W. J., Ullrich A., and McGuire W. L. (1987). Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235, 177–182.

149.	Borg A., Tandon A. K., Sigurdsson H., Clark G. M., Ferno M., Fuqua S. A., et al. (1990). HER-2/neu amplification predicts poor survival in node-positive breast cancer. Cancer Res. 50, 4332–4337.

150.	Hudziak R. M., Lewis G. D., Winget M., Fendly B. M., Shepard H. M., and Ullrich A. (1989). p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor. Mol. Cell Biol. 9, 1165–1172.

151.	Shepard H. M., Lewis G. D., Sarup J. C., Fendly B. M., Maneval D., Mordenti J., et al. (1991). Monoclonal antibody therapy of human cancer: taking the HER2 protooncogene to the clinic. J. Clin. Immunol. 11, 117–127.

152.	Carter P., Presta L., Gorman C. M., Ridgway J. B., Henner D., Wong W. L., et al. (1992). Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc. Natl. Acad. Sci. USA 89, 4285–4289.

153.	Baselga J., Tripathy D., Mendelsohn J., Baughman S., Benz C. C., Dantis L., et al. (1996). Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J. Clin. Oncol. 14, 737–744.

154.	Vici P., Belli F., Di Lauro L., Amodio A., Conti F., Foggi P., et al. (2001). Docetaxel in patients with anthracycline-resistant advanced breast cancer. Oncology 60, 60–65.

155.	Cobleigh M. A., Vogel C. L., Tripathy D., Robert N. J., Scholl S., Fehrenbacher L., et al. (1999). Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J. Clin. Oncol. 17, 2639–2648.

156.	Baselga J., Norton L., Albanell J., Kim Y. M., and Mendelsohn J. (1998). Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res. 58, 2825–2831.

157.	Pietras R. J., Pegram M. D., Finn R. S., Maneval D. A., and Slamon D. J. (1998). Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs. Oncogene 17, 2235–2249.

158.	Slamon D. J., Leyland-Jones B., Shak S., Fuchs H., Paton V., Bajamonde A., et al. (2001). Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344, 783–792.

159.	Tan A. R. and Swain S. M. (2001). Adjuvant chemotherapy for breast cancer: an update. Semin. Oncol. 28, 359–376. <Occurrence Type="DOI"><Handle>10.1016/S0093-7754(01)90130-7</Handle></Occurrence>

160.	Koprowski H., Herlyn D., Lubeck M., DeFreitas E., and Sears H. F. (1984). Human anti-idiotype antibodies in cancer patients: Is the modulation of the immune response beneficial for the patient? Proc. Natl. Acad. Sci. USA 81, 216–219.

161.	LoBuglio A. F., Saleh M. N., Lee J., Khazaeli M. B., Carrano R., Holden H., and Wheeler R. H. (1988). Phase I trial of multiple large doses of murine monoclonal antibody CO17-1A. I. Clinical aspects. J. Natl. Cancer Inst. 80, 932–936.

162.	Riethmuller G., Schneider-Gadicke E., Schlimok G., Schmiegel W., Raab R., Hoffken K., et al. (1994). Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes’ C colorectal carcinoma. German Cancer Aid 17-1A Study Group. Lancet 343, 1177–1183. <Occurrence Type="DOI"><Handle>10.1016/S0140-6736(94)92398-1</Handle></Occurrence>

163.	Gruber R., van Haarlem L. J., Warnaar S. O., Holz E., and Riethmuller G. (2000). The human antimouse immunoglobulin response and the anti-idiotypic network have no influence on clinical outcome in patients with minimal residual colorectal cancer treated with monoclonal antibody CO17-1A. Cancer Res. 60, 1921–1926.

164.	Jerne N. K. (1974). Towards a network theory of the immune system. Ann. Immunol. (Paris) 125C, 373–389.

165.	Frodin J. E., Faxas M. E., Hagstrom B., Lefvert A. K., Masucci G., Nilsson B., et al. (1991). Induction of anti-idiotypic (ab2) and anti-anti-idiotypic (ab3) antibodies in patients treated with the mouse monoclonal antibody 17-1A (ab1). Relation to the clinical outcome—an important antitumoral effector function? Hybridoma 10, 421–431.

166.	Wagner U. A., Oehr P. F., Reinsberg J., Schmidt S. C., Schlebusch H. W., Schultes B., et al. (1992). Immunotherapy of advanced ovarian carcinomas by activation of the idiotypic network. Biotechnol. Ther. 3, 81–89.

167.	Cheung N. K., Cheung I. Y., Canete A., Yeh S. J., Kushner B., Bonilla M. A., et al. (1994). Antibody response to murine anti-GD2 monoclonal antibodies: correlation with patient survival. Cancer Res. 54, 2228–2233.

168.	Schmolling J., Reinsberg J., Wagner U., and Krebs D. (1997). Anti-TAG-72 antibody B72.3 — immunological and clinical effects in ovarian carcinoma. Hybridoma 16, 53–58.

169.	Cheung N. K., Guo H. F., Heller G., and Cheung I. Y. (2000). Induction of Ab3 and Ab3′ antibody was associated with long-term survival after anti-G(D2) antibody therapy of stage 4 neuroblastoma. Clin. Cancer Res. 6, 2653–2660.

170.	Nadler L. M., Stashenko P., Hardy R., Kaplan W. D., Button L. N., Kufe D. W., et al. (1980). Serotherapy of a patient with a monoclonal antibody directed against a human lymphoma-associated antigen. Cancer Res. 40, 3147–3154.

171.	Miller R. A. and Levy R. (1981). Response of cutaneous T cell lymphoma to therapy with hybridoma monoclonal antibody. Lancet 2, 226–230. <Occurrence Type="DOI"><Handle>10.1016/S0140-6736(81)90475-X</Handle></Occurrence>

172.	Cobbold S. P. and Waldmann H. (1984). Therapeutic potential of monovalent monoclonal antibodies. Nature 308, 460–462.

173.	Sahin U., Tureci O., Schmitt H., Cochlovius B., Johannes T., Schmits R., et al. (1995). Human neoplasms elicit multiple specific immune responses in the autologous host. Proc. Natl. Acad. Sci. USA 92, 11,810–11,813.

174.	Barth S., Weidenmuller U., Tur M. K., Schmidt M. F., and Engert A. (2000). Combining phage display and screening of cDNA expression libraries: a new approach for identifying the target antigen of an scFv preselected by phage display. J. Mol. Biol. 301, 751–757.

175.	Chames P., Hufton S. E., Coulie P. G., Uchanska-Ziegler B., and Hoogenboom H. R. (2000). Direct selection of a human antibody fragment directed against the tumor T-cell epitope HLA-A1-MAGE-A1 from a nonimmunized phage-Fab library. Proc. Natl. Acad. Sci. USA 97, 7969–7974.

176.	Li J., Pereira S., Van Belle P., Tsui P., Elder D., Speicher D., et al. (2001). Isolation of the melanoma-associated antigen p23 using antibody phage display. J. Immunol. 166, 432–438.

177.	Herlyn D. M., Steplewski Z., Herlyn M. F., and Koprowski H. (1980). Inhibition of growth of colorectal carcinoma in nude mice by monoclonal antibody. Cancer Res. 40, 717–721.

178.	Hellstrom I., Brown J. P., and Hellstrom K. E. (1981). Monoclonal antibodies to two determinants of melanoma-antigen p97 act synergistically in complement-dependent cytotoxicity. J. Immunol. 127, 157–160.

179.	Herlyn D. and Koprowski H. (1982). IgG2a monoclonal antibodies inhibit human tumor growth through interaction with effector cells. Proc. Natl. Acad. Sci. USA 79, 4761–4765.

180.	Adams D. O., Hall T., Steplewski Z., and Koprowski H. (1984). Tumors undergoing rejection induced by monoclonal antibodies of the IgG2a isotype contain increased numbers of macrophages activated for a distinctive form of antibody-dependent cytolysis. Proc. Natl. Acad. Sci. USA 81, 3506–3510.

181.	Herlyn D., Herlyn M., Ross A. H., Ernst C., Atkinson B., and Koprowski H. (1984). Efficient selection of human tumor growth-inhibiting monoclonal antibodies. J. Immunol. Methods 73, 157–167. <Occurrence Type="DOI"><Handle>10.1016/0022-1759(84)90041-3</Handle></Occurrence>

182.	Hellstrom I., Beaumier P. L., and Hellstrom K. E. (1986). Antitumor effects of L6, an IgG2a antibody that reacts with most human carcinomas. Proc. Natl. Acad. Sci. USA 83, 7059–7063.

183.	Liu A. Y., Robinson R. R., Murray E. D., Jr., Ledbetter J. A., Hellstrom I., and Hellstrom K. E. (1987). Production of a mouse-human chimeric monoclonal antibody to CD20 with potent Fc-dependent biologic activity. J. Immunol. 139, 3521–3526.

184.	Caron P. C., Co M. S., Bull M. K., Avdalovic N. M., Queen C., and Scheinberg D. A. (1992). Biological and Immunological features of humanized M195 (anti-CD33) monoclonal antibodies. Cancer Res. 52, 6761–6767.

185.	Ravetch J. V. and Clynes R. A. (1998). Divergent roles for Fc receptors and complement in vivo. Annu. Rev. Immunol. 16, 421–432.

186.	Bolland S. and Ravetch J. V. (1999). Inhibitory pathways triggered by ITIM-containing receptors. Adv. Immunol. 72, 149–177.

187.	Cragg M. S., French R. R., and Glennie M. J. (1999). Signaling antibodies in cancer therapy. Curr. Opin. Immunol. 11, 541–547. <Occurrence Type="DOI"><Handle>10.1016/S0952-7915(99)00010-2</Handle></Occurrence>

188.	Shan D., Ledbetter J. A., and Press O. W. (1998). Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies. Blood 91, 1644–1652.

189.	Shan D., Ledbetter J. A., and Press O. W. (2000). Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells. Cancer Immunol. Immunother. 48, 673–683.

190.	Ghetie M. A., Podar E. M., Ilgen A., Gordon B. E., Uhr J. W., and Vitetta E. S. (1997). Homodimerization of tumor-reactive monoclonal antibodies markedly increases their ability to induce growth arrest or apoptosis of tumor cells. Proc. Natl. Acad. Sci. USA 94, 7509–7514.

191.	Stout R. D., Suttles J., Xu J., Grewal I. S., and Flavell R. A. (1996). Impaired T cellmediated macrophage activation in CD40 ligand-deficient mice. J. Immunol. 156, 8–11.

192.	van Kooten C. and Banchereau J. (1997). Functions of CD40 on B cells, dendritic cells and other cells. Curr. Opin. Immunol. 9, 330–337. <Occurrence Type="DOI"><Handle>10.1016/S0952-7915(97)80078-7</Handle></Occurrence>

193.	French R. R., Chan H. T., Tutt A. L., and Glennie M. J. (1999). CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help. Nat. Med. 5, 548–553.

194.	Pietras R. J., Poen J. C., Gallardo D., Wongvipat P. N., Lee H. J., and Slamon D. J. (1999). Monoclonal antibody to HER-2/neureceptor modulates repair of radiationinduced DNA damage and enhances radiosensitivity of human breast cancer cells overexpressing this oncogene. Cancer Res. 59, 1347–1355.

195.	Goldenberg D. M., Sharkey R. M., Goldenberg H., Hall T. C., Murthy S., Izon D. O., et al. (1990). Monoclonal antibody therapy of cancer. NJ Med. 87, 913–918.

196.	Chester K. A. and Hawkins R. E. (1995). Clinical issues in antibody design. Trends Biotechnol. 13, 294–300. <Occurrence Type="DOI"><Handle>10.1016/S0167-7799(00)88968-4</Handle></Occurrence>

197.	Adams G. P., Schier R., Marshall K., Wolf E. J., McCall A. M., Marks J. D., and Weiner L. M. (1998). Increased affinity leads to improved selective tumor delivery of single-chain Fv antibodies. Cancer Res. 58, 485–490.

198.	Purtell J. N., Pesce A. J., Clyne D. H., Miller W. C., and Pollak V. E. (1979). Isoelectric point of albumin: effect on renal handling of albumin. Kidney Int. 16, 366–376.

199.	Deen W. M., Bridges C. R., and Brenner B. M. (1983). Biophysical basis of glomerular permselectivity. J. Membr. Biol. 71, 1–10.

200.	Vaughn D. E., Milburn C. M., Penny D. M., Martin W. L., Johnson J. L., and Bjorkman P. J. (1997). Identification of critical IgG binding epitopes on the neonatal Fc receptor. J. Mol. Biol. 274, 597–607.

201.	Junghans R. P. and Anderson C. L. (1996). The protection receptor for IgG catabolism is the beta2-microglobulin-containing neonatal intestinal transport receptor. Proc. Natl. Acad. Sci. USA 93, 5512–5516.

202.	Ghetie V., Popov S., Borvak J., Radu C., Matesoi D., Medesan C., et al. (1997). Increasing the serum persistence of an IgG fragment by random mutagenesis. Nat. Biotechnol. 15, 637–640.

203.	Ghetie V. and Ward E. S. (1997). FcRn: the MHC class I-related receptor that is more than an IgG transporter. Immunol. Today 18, 592–598. <Occurrence Type="DOI"><Handle>10.1016/S0167-5699(97)01172-9</Handle></Occurrence>

204.	Zuckier L. S., Chang C. J., Scharff M. D., and Morrison S. L. (1998). Chimeric human-mouse IgG antibodies with shuffled constant region exons demonstrate that multiple domains contribute to in vivo half-life. Cancer Res. 58, 3905–3908.

205.	Milenic D. E., Yokota T., Filpula D. R., Finkelman M. A., Dodd S. W., Wood J. F., et al. (1991). Construction, binding properties, metabolism, and tumor targeting of a single-chain Fv derived from the pancarcinoma monoclonal antibody CC49. Cancer Res. 51, 6363–6371.

206.	Huston J. S., George A. J., Adams G. P., Stafford W. F., Jamar F., Tai M. S., et al. (1996). Single-chain Fv radioimmunotargeting. Q. J. Nucl. Med. 40, 320–333.

207.	Adams G. P., Schier R., McCall A. M., Crawford R. S., Wolf E. J., Weiner L. M., and Marks J. D. (1998). Prolonged in vivo tumour retention of a human diabody targeting the extracellular domain of human HER2/neu. Br. J. Cancer 77, 1405–1412.

208.	Yokota T., Milenic D. E., Whitlow M., and Schlom J. (1992). Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms. Cancer Res. 52, 3402–3408.

209.	Boerman O. C., Mijnheere E. P., Broers J. L., Vooijs G. P., and Ramaekers F. C. (1991). Biodistribution of a monoclonal antibody (RNL-1) against the neural cell adhesion molecule (NCAM) in athymic mice bearing human small-cell lung-cancer xenografts. Int. J. Cancer 48, 457–462.

210.	Kennel S. J., Falcioni R., and Wesley J. W. (1991). Microdistribution of specific rat monoclonal antibodies to mouse tissues and human tumor xenografts. Cancer Res. 51, 1529–1536.

211.	Clauss M. A. and Jain R. K. (1990). Interstitial transport of rabbit and sheep antibodies in normal and neoplastic tissues. Cancer Res. 50, 3487–3492.

212.	Colcher D., Bird R., Roselli M., Hardman K. D., Johnson S., Pope S., et al. (1990). In vivo tumor targeting of a recombinant single-chain antigen-bindin protein. J. Natl. Cancer Inst. 82, 1191–1197.

213.	Adams G. P., McCartney J. E., Tai M. S., Oppermann H., Huston J. S., Stafford W. F. D., et al. (1993). Highly specific in vivo tumor targeting by monovalent and divalent forms of 741F8 anti-c-erbB-2 single-chain Fv. Cancer Res. 53, 4026–4034.

214.	Kitamura K., Takahashi T., Yamaguchi T., Noguchi A., Takashina K., Tsurumi H., et al. (1991). Chemical engineering of the monoclonal antibody A7 by polyethylene glycol for targeting cancer chemotherapy. Cancer Res. 51, 4310–4315.

215.	Pedley R. B., Boden J. A., Boden R., Begent R. H., Turner A., Haines A. M., and King D. J. (1994). The potential for enhanced tumour localisation by poly(ethylene glycol) modification of anti-CEA antibody. Br. J. Cancer 70, 1126–1130.

216.	Chapman A. P., Antoniw P., Spitali M., West S., Stephens S., and King D. J. (1999). Therapeutic antibody fragments with prolonged in vivo half-lives. Nature Biotechnol. 17, 780–783.

217.	Abuchowski A., McCoy J. R., Palczuk N. C., van Es T., and Davis F. F. (1977). Effect of covalent attachment of polyethylene glycol on immunogenicity and circulating life of bovine liver catalase. J. Biol. Chem. 252, 3582–3586.

218.	Marks J. D., Griffiths A. D., Malmqvist M., Clackson T. P., Bye J. M., and Winter G. (1992). By-passing immunization: building high affinity human antibodies by chain shuffling. Biotechnology (NY) 10, 779–783.

219.	Hawkins R. E., Russell S. J., Baier M., and Winter G. (1993). The contribution of contact and non-contact residues of antibody in the affinity of binding to antigen. The interaction of mutant D1.3 antibodies with lysozyme. J. Mol. Biol. 234, 958–964.

220.	Schier R., McCall A., Adams G. P., Marshall K. W., Merritt H., Yim M., et al. (1996). Isolation of picomolar affinity anti-c-erbB-2 single-chain Fv by molecular evolution of the complementarity determining regions in the center of the antibody binding site. J. Mol. Biol. 263, 551–567.

221.	Schier R., Marks J. D., Wolf E. J., Apell G., Wong C., McCartney J. E., et al. (1995). In vitro and in vivo characterization of a human anti-c-erbB-2 single-chain Fv isolated from a filamentous phage antibody library. Immunotechnology 1, 73–81. <Occurrence Type="DOI"><Handle>10.1016/1380-2933(95)00007-0</Handle></Occurrence>

222.	Schier R., Bye J., Apell G., McCall A., Adams G. P., Malmqvist M., et al. (1996). Isolation of high-affinity monomeric human anti-c-erbB-2 single chain Fv using affinity-driven selection. J. Mol. Biol. 255, 28–43.

223.	Adams G. P., Schier R., McCall A., Wolf E. J., Marks J. D., and Weiner L. M. (1996). Tumor targeting properties of anti-c-erb-2 single-chain Fv molecules over a wide range of affinities for the same epitope. Tumor Targeting 2, 154.

224.	Weinstein J. N., Eger R. R., Covell D. G., Black C. D., Mulshine J., Carrasquillo J. A., et al. (1987). The pharmacology of monoclonal antibodies. Ann. NY Acad. Sci. 507, 199–210.

225.	Adams G. P., Schier R., McCall A. M., Simmons H. H., Horak E. M., Alpaugh R. K., Marks J. D., and Weiner L. M. (2001). High affinity restricts the localization and tumor penetration of single-chain Fv antibody molecules. Cancer Res. 61, 4750–4755.

226.	Crothers D. M. and Metzger H. (1972). The influence of polyvalency on the binding properties of antibodies. Immunochemistry 9, 341–357. <Occurrence Type="DOI"><Handle>10.1016/0019-2791(72)90097-3</Handle></Occurrence>

227.	Wu A. M., Chen W., Raubitschek A., Williams L. E., Neumaier M., Fischer R., et al. (1996). Tumor localization of anti-CEA single-chain Fvs: improved targeting by noncovalent dimers. Immunotechnology 2, 21–36. <Occurrence Type="DOI"><Handle>10.1016/1380-2933(95)00027-5</Handle></Occurrence>

228.	Goel A., Colcher D., Baranowska-Kortylewicz J., Augustine S., Booth B. J., Pavlinkova G., and Batra S. K. (2000). Genetically engineered tetravalent single-chain Fv of the pancarcinoma monoclonal antibody CC49: improved biodistribution and potential for therapeutic application. Cancer Res. 60, 6964–6971.

229.	Nielsen U. B., Adams G. P., Weiner L. M., and Marks J. D. (2000). Targeting of bivalent anti-ErbB2 diabody antibody fragments to tumor cells is independent of the intrinsic antibody affinity. Cancer Res. 60, 6434–6440.

Comments (Loading...)

Post comment/View all comments